Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29657636 | 0.68 | CYP1A1 (0.40) | HTR2AHTR2CHTR2BNFKB1MAOA | |
| SCHEMBL8553982 | 0.68 | CYP1A1 (0.40) | HTR2AHTR2CHTR2BNFKB1MAOA | |
| SCHEMBL4429415 | 0.66 | PAX8 (0.48) | HTR2AHTR2CHTR2BNFKB1MAOA | |
| SCHEMBL31590672 | 0.65 | — | — | |
| SCHEMBL13714647 | 0.64 | HTR2A (0.30) | HTR2AHTR2CHTR2B | |
| SCHEMBL15465932 | 0.61 | PAX8 (0.45) | HTR2AHTR2CHTR2BNFKB1MAOA | |
| SCHEMBL12278144 | 0.61 | PAX8 (0.45) | HTR2AHTR2CHTR2BNFKB1MAOA | |
| SCHEMBL17426271 | 0.61 | PAX8 (0.45) | HTR2AHTR2CHTR2BNFKB1MAOA | |
| SCHEMBL1037692 | 0.60 | HTR2C (0.36) | HTR2AHTR2CHTR2BNFKB1MAOA | |
| SCHEMBL1555758 | 0.59 | MAOA (0.41) | HTR2AHTR2CHTR2BNFKB1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040023290-A1 | Novel therapeutic agents that modulate enzymatic processes | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-02-05 | — | — | US | claimed |
| EP-0989857-A4 | NOVEL THERAPEUTIC AGENTS THAT MODULATE ENZYMATIC PROCESSES | ADVANCED MEDICINE INC (US) | 2001-01-17 | — | — | EP | claimed |
| EP-0989857-A1 | NOVEL THERAPEUTIC AGENTS THAT MODULATE ENZYMATIC PROCESSES | Advanced Medicine, Inc. (US) | 2000-04-05 | — | — | EP | claimed |
| WO-1999064037-A1 | NOVEL THERAPEUTIC AGENTS THAT MODULATE ENZYMATIC PROCESSES | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | claimed |
| EP-0429464-B1 | BIVALENT LIGANDS EFFECTIVE FOR BLOCKING ACAT ENZYME | UPJOHN CO (US) | 1994-11-23 | — | — | EP | disclosed |
| US-5304548-A | Tether composition joining two furochromones | THE UPJOHN COMPANY (US) | 1994-04-19 | — | — | US | disclosed |
| US-5180717-A | Atherosclerosis treatment and antilipemic agents | THE UPJOHN COMPANY (US) | 1993-01-19 | — | — | US | disclosed |
| EP-0429464-A1 | BIVALENT LIGANDS EFFECTIVE FOR BLOCKING ACAT ENZYME. | UPJOHN CO (US) | 1991-06-05 | — | — | EP | disclosed |
| WO-1990002129-A1 | BIVALENT LIGANDS EFFECTIVE FOR BLOCKING ACAT ENZYME | THE UPJOHN COMPANY (US) | 1990-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023290-A1 | Novel therapeutic agents that modulate enzymatic processes | RNASE1, ENGASE, ENTPD5 | HTR2A 4688/4885HTR2C 4755/4885HTR2B 4623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.